CD8A and cancer: The recent success using checkpoints inhibitors in the cancer field [46], have started to be introduced in preclinical models of HIV with the objective to preserve the function of HIV-specific CD8+ T cells from exhaustion and target directly HIV cell reservoir [47–49].